Bakaćs T, Garam T, Ringwald G, Tótpál K, Svastits E
Arch Geschwulstforsch. 1981;51(4):327-37.
Peripheral blood lymphocytes of 84 patients with mammary tumors (73 malignant, 11 benign diseases) and 79 healthy female blood donors were tested in three cytotoxicity assays. Natural cell mediated cytotoxicity (NCMC) was measured against K562 cell line, antibody dependent cellular cytotoxicity (ADCC) was tested against K562 cell line sensitized with hyperimmune rabbit anti K562 sera and human 0, Rh positive (C, D, E pos.) erythrocytes sensitized with Ripley antibodies. Effector cell activity was measured as a function of the target cell number in the new cytotoxic capacity test. Maximums were determined experimentally and also by extrapolation from the measured values using the Michaelis-Menten equation. It was found, that activity of patients was lower than that of the controls in all the three tests already at an early stage of the malignant disease. Therefore introduction of the new cytotoxic capacity test to screen NCMC and ADCC is suggested.
对84例乳腺肿瘤患者（73例恶性肿瘤，11例良性疾病）及79名健康女性献血者的外周血淋巴细胞进行了三项细胞毒性试验。针对K562细胞系测定自然细胞介导的细胞毒性（NCMC），针对用超免疫兔抗K562血清致敏的K562细胞系以及用里普利抗体致敏的人O型、Rh阳性（C、D、E阳性）红细胞测定抗体依赖性细胞毒性（ADCC）。在新的细胞毒性能力试验中，作为靶细胞数量的函数来测量效应细胞活性。通过实验确定最大值，并使用米氏方程从测量值外推得出。结果发现，在恶性疾病的早期阶段，所有三项试验中患者的活性均低于对照组。因此，建议采用新的细胞毒性能力试验来筛查NCMC和ADCC。
